Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call lacks positive financial indicators, with no revenue reported and increasing net losses due to rising R&D and administrative expenses. The company's cash reserves are also decreasing. Despite strategic initiatives, the absence of immediate revenue and the acknowledgment of risks in forward-looking statements contribute to a negative sentiment. The lack of discussion on shareholder returns further weakens the outlook. Given these factors, the stock price is likely to experience a negative movement over the next two weeks.
Key Financial Performance
Revenue No revenue was reported for the first quarter of 2026, consistent with the prior year, as the company remains in the development stage.
Net Loss Net loss for Q1 2026 was $20.3 million, compared to $15.7 million in Q1 2025, representing a year-over-year increase of 29%. The increase was primarily due to higher research and development expenses.
Research and Development Expenses R&D expenses were $15.2 million in Q1 2026, up from $11.4 million in Q1 2025, marking a 33% increase. This rise was attributed to increased clinical trial activities and personnel-related costs.
General and Administrative Expenses G&A expenses were $5.6 million in Q1 2026, compared to $4.5 million in Q1 2025, reflecting a 24% increase. The increase was due to higher personnel costs and professional fees.
Cash and Cash Equivalents Cash and cash equivalents were $120.5 million as of March 31, 2026, compared to $135.8 million as of December 31, 2025. The decrease was due to operational expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements are subject to risks and uncertainties, which could lead to actual results differing materially and adversely from expectations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Development Activities: Viking's expectations regarding its development activities, timelines, and milestones.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Amin Piper
Aubuchon Chief
Biren Amin
Blair LLC
Blake Gitler
Brian Lian
Charoensook Leerink
Co Research
Deschner Raymond
Division Annabel
Division Biren
Division Hardik
Division Jay
Division Nathanael
Division Ryan
Division Wood
EDT Vida
Gitler BTIG
Hsieh Blair
Inc Blake
Inc Research
Jay Olson
LLC Research
Laidlaw PM
Neil Aubuchon
Officer Neil
Officer Seedhouse
PM EDT
Partners
Piper Sandler
Raymond Associates
Relations comment
Research Division
VKTX Transcript
Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript
Unknown4-30
The earnings call lacks positive financial indicators, with no revenue reported and increasing net losses due to rising R&D and administrative expenses. The company's cash reserves are also decreasing. Despite strategic initiatives, the absence of immediate revenue and the acknowledgment of risks in forward-looking statements contribute to a negative sentiment. The lack of discussion on shareholder returns further weakens the outlook. Given these factors, the stock price is likely to experience a negative movement over the next two weeks.
Viking Therapeutics, Inc. (VKTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-10
Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
Unknown2-12
The earnings call indicates mixed signals: increased net loss due to R&D costs, but a promising pipeline with Phase III trials and a new amylin program. The Q&A reveals management's reluctance to disclose specifics, which raises uncertainties. Despite strong cash reserves, the lack of clear guidance and strategic partnerships tempers optimism. Overall, the sentiment remains neutral as positive developments are balanced by uncertainties and financial pressures.
Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
VKTX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
